Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (8743)	6/23/2003 9:49:54 AM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Well R&D at BGEN has been something of a disappointment - seems to me they have never quite recovered from the CD40L failure. Aside from Antegren, I'm not sure there's much there - but I don't follow them that closely, and so I am open to correction. Mostly my impression is one of passivity - they have plenty of resources, but seemingly never had the get-up-and-go to do anything with them. (Any company of that size and up with even a modicum of business sense should have gone out and gobbled SEPR when it was out there with the stock under $5, for example). I've owned BGEN never in size) a few times, invariably with exquisitely bad timing. Peter